These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 23176372

  • 1. Cyclophosphamide-hydroxycamptothecin as second-line chemotherapy for advanced Ewing's sarcoma: experience of a single institution.
    Han K, Sun Y, Zhang J, He A, Zheng S, Shen Z, Yao Y.
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e114-7. PubMed ID: 23176372
    [Abstract] [Full Text] [Related]

  • 2. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S, Mercuri M, Rosito P, Mancini A, Barbieri E, Longhi A, Rimondini S, Cesari M, Ruggieri P, Di Liddo M, Bacci G.
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
    Tural D, Molinas Mandel N, Dervisoglu S, Oner Dincbas F, Koca S, Colpan Oksuz D, Kantarci F, Turna H, Selcukbiricik F, Hiz M.
    Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
    [Abstract] [Full Text] [Related]

  • 5. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Grier HE.
    J Clin Oncol; 2004 Jul 15; 22(14):2873-6. PubMed ID: 15254055
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment.
    Argon A, Basaran M, Yaman F, Dizdar Y, Sakar B, Camlica H, Bavbek SE, Ozger H, Darendeliler E, Onat H.
    Jpn J Clin Oncol; 2004 Nov 15; 34(11):667-72. PubMed ID: 15613556
    [Abstract] [Full Text] [Related]

  • 8. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
    Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA, Pratt CB, Greenwald C, Meyer WH.
    J Clin Oncol; 1999 Jan 15; 17(1):180-90. PubMed ID: 10458232
    [Abstract] [Full Text] [Related]

  • 9. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
    Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, Imeson J, Lewis I.
    J Clin Oncol; 1998 Nov 15; 16(11):3628-33. PubMed ID: 9817284
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
    Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P.
    J Clin Oncol; 2000 Jan 15; 18(1):4-11. PubMed ID: 10623687
    [Abstract] [Full Text] [Related]

  • 12. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
    Bacci G, Picci P, Ruggieri P, Ferrari S, Mercuri M, Fabbri N, Rosito P, Barbieri E, Ferraro A, Casadei R.
    J Chemother; 1993 Aug 15; 5(4):247-57. PubMed ID: 8229153
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
    Bacci G, Picci P, Ferrari S, Mercuri M, Brach del Prever A, Rosito P, Barbieri E, Tienghi A, Forni C.
    Cancer; 1998 Mar 15; 82(6):1174-83. PubMed ID: 9506366
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F, Santana VM, Billups CA, Merchant TE, Furman WL, Spunt SL, Cain AM, Rao BN, Hale GA, Pappo AS.
    Cancer; 2006 Apr 15; 106(8):1846-56. PubMed ID: 16541446
    [Abstract] [Full Text] [Related]

  • 18. Extraskeletal Ewing's sarcoma.
    Ahmad R, Mayol BR, Davis M, Rougraff BT.
    Cancer; 1999 Feb 01; 85(3):725-31. PubMed ID: 10091746
    [Abstract] [Full Text] [Related]

  • 19. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
    Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E.
    Pediatr Hematol Oncol; 2013 Apr 01; 30(3):170-7. PubMed ID: 23484903
    [Abstract] [Full Text] [Related]

  • 20. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.
    Bacci G, Picci P, Mercuri M, Ferrari S, Longhi A, Cesari M, Rosito P, Mancini AF, Barbieri E, Baldini N.
    Acta Oncol; 1998 Apr 01; 37(7-8):671-6. PubMed ID: 10050985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.